Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02487 科笛-B
Listing Date2023/06/12
Listing Price21.850
  • 7.590 -0.360 (-4.528%)    Sink Below Listing Price
  • 15-min delayed, last update: 27/05/2024 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

Cutia Therapeutics founded in 2019, it is an R&D-driven, dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care and topical anesthesia.


The Group have one Core Product and eight other pipeline product candidates. It also distributed two commercialized products developed by overseas collaboration partners. Its Core Product, CU-20401, is a recombinant mutant collagenase. It held one patent in relation to its Core Product.


The Group conducts business under the brand name “Cutia”. It had 140 registered trademarks and filed 66 trademark applications in Mainland China and Hong Kong. It held 24 patents and patent applications including in-licensed patents and patent applications in Mainland China, Hong Kong and Japan.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares21.28M shares
No. of International Offer Shares19.15M shares
No. of HK Offer Shares2.13M shares
Offer Price$20.65 - $24.75
Stock Code2487
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, Deutsche Bank AG, Hong Kong Branch, CLSA Limited, Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited, BOCI Asia Limited, UOB Kay Hian (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited, Valuable Capital Limited, Silverbricks Securities Company Limited, Tiger Brokers (HK) Global Limited
Application PeriodMay 31 (Wed) - noon, Jun 05 (Mon)
Price Determination DateJun 05 (Mon)
Result Announcement DateOn or before Jun 09 (Fri)
Result Announcement DateOn or before Jun 09 (Fri)
Result Announcement DateOn or before Jun 09 (Fri)
Dealings in Shares commence onJun 12, 2023. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$20.65 - $24.75
Capitalization6.28B - 7.53B
NAV / share ($)$6.15 - $6.42 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 22.7, the net proceeds raised would be HKD 412.90M, of which
45% : Used for Core Product CU-20401
22% : Fund the continuing R&D activities of Key Products, CU-40102 and CU-10201
18% : Fund the continuing R&D activities of the other candidates in pipeline
10% : Technology development and business development for pipeline expansion
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.